Cargando…
Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study
BACKGROUND: There is no consensus regarding the optimal time to initiate adjuvant chemotherapy after surgery for stage III colon cancer, and the relevant postoperative complications that cause delays in adjuvant chemotherapy are unknown. METHODS: Eligible patients aged ≥66 years who were diagnosed w...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831576/ https://www.ncbi.nlm.nih.gov/pubmed/29490625 http://dx.doi.org/10.1186/s12885-018-4138-7 |
_version_ | 1783303163435024384 |
---|---|
author | Gao, Peng Huang, Xuan-zhang Song, Yong-xi Sun, Jing-xu Chen, Xiao-wan Sun, Yu Jiang, Yu-meng Wang, Zhen-ning |
author_facet | Gao, Peng Huang, Xuan-zhang Song, Yong-xi Sun, Jing-xu Chen, Xiao-wan Sun, Yu Jiang, Yu-meng Wang, Zhen-ning |
author_sort | Gao, Peng |
collection | PubMed |
description | BACKGROUND: There is no consensus regarding the optimal time to initiate adjuvant chemotherapy after surgery for stage III colon cancer, and the relevant postoperative complications that cause delays in adjuvant chemotherapy are unknown. METHODS: Eligible patients aged ≥66 years who were diagnosed with stage III colon cancer from 1992 to 2008 were identified using the linked Surveillance, Epidemiology, and End Results-Medicare database. Kaplan-Meier analysis and a Cox proportional hazards model were utilized to evaluate the impact of the timing of adjuvant chemotherapy on overall survival (OS). RESULTS: A total of 18,491 patients were included. Delayed adjuvant chemotherapy was associated with worse OS (9–12 weeks: hazard ratio [HR] = 1.222, 95% confidence interval [CI] = 1.063–1.405; 13–16 weeks: HR = 1.252, 95% CI = 1.041–1.505; ≥ 17 weeks: HR = 1.969, 95% CI = 1.663–2.331). The efficacies of adjuvant chemotherapy within 5–8 weeks and ≤4 weeks were similar (HR = 1.045, 95% CI = 0.921–1.185). Compared with the non-chemotherapy group, chemotherapy initiated at ≥21 weeks did not significantly improve OS (HR = 0.882, 95% CI = 0.763–1.018). Patients with postoperative complications, particularly cardiac arrest, ostomy infection, shock, and septicemia, had a significantly higher risk of a 4- to 11-week delay in adjuvant chemotherapy (p < 0.05). CONCLUSIONS: Adjuvant chemotherapy initiated within 8 weeks was acceptable for patients with stage III colon cancer. Delayed adjuvant chemotherapy after 8 weeks was significantly associated with worse OS. However, adjuvant chemotherapy might still be useful even with a delay of approximately 5 months. Moreover, postoperative complications were significantly associated with delayed adjuvant chemotherapy. |
format | Online Article Text |
id | pubmed-5831576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58315762018-03-05 Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study Gao, Peng Huang, Xuan-zhang Song, Yong-xi Sun, Jing-xu Chen, Xiao-wan Sun, Yu Jiang, Yu-meng Wang, Zhen-ning BMC Cancer Research Article BACKGROUND: There is no consensus regarding the optimal time to initiate adjuvant chemotherapy after surgery for stage III colon cancer, and the relevant postoperative complications that cause delays in adjuvant chemotherapy are unknown. METHODS: Eligible patients aged ≥66 years who were diagnosed with stage III colon cancer from 1992 to 2008 were identified using the linked Surveillance, Epidemiology, and End Results-Medicare database. Kaplan-Meier analysis and a Cox proportional hazards model were utilized to evaluate the impact of the timing of adjuvant chemotherapy on overall survival (OS). RESULTS: A total of 18,491 patients were included. Delayed adjuvant chemotherapy was associated with worse OS (9–12 weeks: hazard ratio [HR] = 1.222, 95% confidence interval [CI] = 1.063–1.405; 13–16 weeks: HR = 1.252, 95% CI = 1.041–1.505; ≥ 17 weeks: HR = 1.969, 95% CI = 1.663–2.331). The efficacies of adjuvant chemotherapy within 5–8 weeks and ≤4 weeks were similar (HR = 1.045, 95% CI = 0.921–1.185). Compared with the non-chemotherapy group, chemotherapy initiated at ≥21 weeks did not significantly improve OS (HR = 0.882, 95% CI = 0.763–1.018). Patients with postoperative complications, particularly cardiac arrest, ostomy infection, shock, and septicemia, had a significantly higher risk of a 4- to 11-week delay in adjuvant chemotherapy (p < 0.05). CONCLUSIONS: Adjuvant chemotherapy initiated within 8 weeks was acceptable for patients with stage III colon cancer. Delayed adjuvant chemotherapy after 8 weeks was significantly associated with worse OS. However, adjuvant chemotherapy might still be useful even with a delay of approximately 5 months. Moreover, postoperative complications were significantly associated with delayed adjuvant chemotherapy. BioMed Central 2018-03-01 /pmc/articles/PMC5831576/ /pubmed/29490625 http://dx.doi.org/10.1186/s12885-018-4138-7 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Gao, Peng Huang, Xuan-zhang Song, Yong-xi Sun, Jing-xu Chen, Xiao-wan Sun, Yu Jiang, Yu-meng Wang, Zhen-ning Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study |
title | Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study |
title_full | Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study |
title_fullStr | Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study |
title_full_unstemmed | Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study |
title_short | Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study |
title_sort | impact of timing of adjuvant chemotherapy on survival in stage iii colon cancer: a population-based study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831576/ https://www.ncbi.nlm.nih.gov/pubmed/29490625 http://dx.doi.org/10.1186/s12885-018-4138-7 |
work_keys_str_mv | AT gaopeng impactoftimingofadjuvantchemotherapyonsurvivalinstageiiicoloncancerapopulationbasedstudy AT huangxuanzhang impactoftimingofadjuvantchemotherapyonsurvivalinstageiiicoloncancerapopulationbasedstudy AT songyongxi impactoftimingofadjuvantchemotherapyonsurvivalinstageiiicoloncancerapopulationbasedstudy AT sunjingxu impactoftimingofadjuvantchemotherapyonsurvivalinstageiiicoloncancerapopulationbasedstudy AT chenxiaowan impactoftimingofadjuvantchemotherapyonsurvivalinstageiiicoloncancerapopulationbasedstudy AT sunyu impactoftimingofadjuvantchemotherapyonsurvivalinstageiiicoloncancerapopulationbasedstudy AT jiangyumeng impactoftimingofadjuvantchemotherapyonsurvivalinstageiiicoloncancerapopulationbasedstudy AT wangzhenning impactoftimingofadjuvantchemotherapyonsurvivalinstageiiicoloncancerapopulationbasedstudy |